Inflammatory Bowel Disease · Article 150

How Should Biologic Therapy Be Managed Around Surgery in IBD?

IBD biologic surgery requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

IBD biologic surgery clinical reference — Related free clinical resource: First Principles of Gastroenterology and Hepatology.

IBD biologic surgery: practical clinical approach

This page focuses on IBD biologic surgery with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for IBD biologic surgery

Clinical takeaway: For IBD biologic surgery, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Perioperative biologic management should focus less on arbitrary drug washout and more on overall surgical risk. Contemporary Crohn’s guidance does not support delaying necessary surgery solely to create prolonged biologic-free intervals. Control sepsis, correct malnutrition and anemia, and reduce corticosteroids when possible—these factors often matter more than biologic exposure. Timing of postoperative restart depends on wound healing, infection risk and the need to prevent Crohn’s recurrence.

Biologic exposure is only one risk variable

Disease severity itself confounds many observational studies. Steroids, malnutrition, abscesses and emergency surgery consistently carry important postoperative risk.

Do not delay necessary surgery for a theoretical washout

When surgery is indicated, prolonged delay can worsen obstruction, sepsis or nutritional decline.

Plan postoperative therapy before the operation

High-risk Crohn’s patients may need early postoperative advanced therapy for recurrence prevention.

Practical clinical algorithm

1. Review biologic type, last dose and disease activity.

2. Drain sepsis and optimize nutrition/anemia.

3. Reduce systemic corticosteroids where safely possible.

4. Do not postpone necessary surgery solely for biologic washout.

5. Restart or initiate postoperative preventive therapy according to healing and recurrence risk.

Common mistakes to avoid

Focusing on biologic timing while ignoring steroids and malnutrition.
Delaying urgent surgery for a full dosing interval.
Automatically stopping all biologics weeks before elective surgery.
Failing to plan postoperative recurrence prevention.
Restarting therapy in uncontrolled postoperative infection.

Trainee takeaway

Perioperative success is driven by global optimization; biologic timing is one part of the picture, not the whole picture.

Frequently asked questions

Should anti-TNF always be stopped before surgery?

No. Current surgical guidance supports individualized management rather than routine prolonged withdrawal.

What factor is often more concerning than biologic exposure?

Systemic corticosteroid exposure, malnutrition and active sepsis.

When should biologic therapy restart?

After adequate postoperative recovery and infection control, balanced against recurrence risk.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Guideline-Based Management in Gastroenterology. CAPstone Academic Publishers; 2015.

3. Adamina M, Minozzi S, Warusavitarne J, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. J Crohns Colitis. 2024;18:1556-1582.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions